 | | Vol. 11.18 – 11 May, 2022 |
| |
|
|
Spatial Epitranscriptomics Reveals A-to-I Editome Specific to Cancer Stem Cell Microniches | The authors introduced spatial-histopathological examination-linked epitranscriptomics converged to transcriptomics with sequencing, which isolated regions of interest from immunofluorescence-stained tissue and obtained transcriptomic and epitranscriptomic data.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
NAT10-Mediated mRNA N4-Acetylcytidine Modification Promotes Bladder Cancer Progression | Acetylated RNA immunoprecipitation sequencing was utilized to explore the role of N-acetyltransferase 10 (NAT10) in mRNA N4-acetylcytidine modification.
[Clinical and Translational Medicine] |
|
|
|
Targeting DCLK1 Overcomes 5-Fluorouracil Resistance in Colorectal Cancer through Inhibiting CCAR1/β-Catenin Pathway-Mediated Cancer Stemness | Researchers established 5-fluorouracil resistant cell lines and explored the potential targets associated with 5-fluorouracil resistance in colorectal cancer.
[Clinical and Translational Medicine] |
|
|
|
Endothelial Nitric Oxide Synthase (eNOS)-NO Signaling Axis Functions to Promote the Growth of Prostate Cancer Stem-Like Cells | The regulatory functions of NOS-nitric oxide signaling were evaluated in prostate cancer cells, especially in prostate cancer stem-like cells enriched by 3D spheroid culture and CD133/CD44 cell sorting.
[Stem Cell Research & Therapy] |
|
|
|
Infiltrating Natural Killer Cells Bind, Lyse and Increase Chemotherapy Efficacy in Glioblastoma Stem-Like Tumorospheres | Immunotherapy with super-charged natural killer cells has a potential as antitumor approach since the authors found their efficiency to kill patient-derived glioblastoma stem-like cells in 2D and 3D models, potentially reversing the immunosuppression also seen in the patients.
[Communications Biology] |
|
|
|
Characterization of Immunogenicity of Malignant Cells with Stemness in Intrahepatic Cholangiocarcinoma by Single-Cell RNA Sequencing | Researchers used single-cell transcriptomic data to study immunogenicity of malignant cells in human intrahepatic cholangiocarcinoma.
[Stem Cells International] |
|
|
|
Transcriptome Profiling Reveals That VNPP433-3β, the Lead Next-Generation Galeterone Analog Inhibits Prostate Cancer Stem Cells by Downregulating Epithelial–Mesenchymal Transition and Stem Cell Markers | In this study using RNA-seq, cytological, and biochemical methods, scientists reported that VNPP433-3β inhibited prostate CSCs by targeting key pathways critical to stemness and epithelial–mesenchymal transition.
[Molecular Carcinogenesis] |
|
|
|
Monocarboxylate Transporter 1 Is a Novel Target for Breast Cancer Stem Like-Cell Inhibition by Diallyl Trisulfide | Western blot analysis confirmed increased expression of monocarboxylate transporter 1 protein in SUM159 and MCF-7 cells stably transfected to overexpress forkhead box Q1.
[Molecular Carcinogenesis] |
|
|
|
Cytotoxic Effect of Disulfiram/Copper on Human Cervical Cancer Cell Lines and LGR5-Positive Cancer Stem-Like Cells | Scientists reported that high aldehyde dehydrogenase activity represented a functional marker for cervical cancer stem cells.
[BMC Cancer] |
|
|
|
Blockade of p38 MAPK Overcomes AML Stem Cell Line KG1a Resistance to 5-Fluorouridine and the Impact on miRNA Profiling | Researchers targeted the survival pathway p38 MAPK, NF-κB and ROS generation in human chemoresistant acute myeloid leukemia stem cell line KG1a, susceptible to enhance cell sensitivity to the chemotherapy drug 5-Fluorouridine, compared to the chemosensitive AML cell line HL60.
[PLoS One] |
|  |
|
|
|
The Application of Cancer Stem Cell Model in Malignant Mesothelioma | The main methods to characterize isolated CSCs include sphere formation, invasiveness, tumor-initiating capacity and expression of specific surface markers.
[Critical Reviews in Oncology/Hematology] |
|
|
|
Quiescence Regulation by Normal Hematopoietic Stem Cells and Leukemia Stem Cells | Quiescence provides essential protection for both hematopoietic stem cells and leukemia stem cells (LSCs) from cytotoxic stress and DNA damage and, in the case of LSCs, likely causes therapy resistance and disease relapse in leukemia patients.
[FEBS Journal] |
|
|
|
|
Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) – Expressing Cancers | Cue Biopharma, Inc. announced that the US FDA has accepted the Company’s Investigational New Drug application for the evaluation of CUE-102, its second interleukin 2 (IL-2)-based CUE-100 series biologic, in a dose escalation and expansion monotherapy Phase I trial.
[Cue Biopharma] |
|
|
|
|
| May 30 – June 1, 2022
Brisbane, Queensland, Australia |
|
|
|
|
|
| | Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
| | Institute of Cancer Research – London, United Kingdom |
|
|
|
| Johns Hopkins University – Baltimore, Maryland, United States |
|
|
|
| | McGill University – Montreal, Quebec, Canada |
|
|
|
| Cyprus Cancer Research Institute – Nicosia, Cyprus |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
